Kim Han-Na, Januzzi James L
Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA, 02114, USA.
Curr Treat Options Cardiovasc Med. 2010 Dec;12(6):519-31. doi: 10.1007/s11936-010-0096-3.
Biomarkers, especially natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard clinical assessment in the diagnosis and prognosis of heart failure (HF). Furthermore, there is an increasing amount of evidence suggesting that natriuretic peptide-guided HF management may improve mortality, morbidity, and cost effectiveness. This work focuses on the use of BNP or NT-proBNP for the outpatient management of patients with chronic HF.
生物标志物，尤其是利钠肽，如B型利钠肽（BNP）和N末端前脑钠肽原（NT-proBNP），是标准临床评估在心力衰竭（HF）诊断和预后中的重要补充。此外，越来越多的证据表明，利钠肽指导的HF管理可能会改善死亡率、发病率和成本效益。这项工作重点关注BNP或NT-proBNP在慢性HF患者门诊管理中的应用。
